SEC EDGARJUN 11 min read$ILMN

Meister Keith A. sold $107.0M of ILMN (indirect holdings)

Meister Keith A. sold 669,596 indirectly-held shares of ILLUMINA, INC. (ILMN) at an average of $159.86 ($147.50–$165.50, $107.04M total) across 17 trades over 2026-05-28 to 2026-06-01.

Original reporting

SEC EDGAR · Meister Keith A.

Published Jun 1, 2026, 10:04 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 28, 2026, 3:42 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$ILMN

Bearish

medium confidence

Mentioned

$ILMN

Relevance

8/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ILMNBearishLow

Why it matters

The $107M sale by a director is a material insider transaction that can influence short‑term price dynamics.

Market read

Large insider sell creates potential downside pressure for Illumina; traders may watch for price reaction.

What to watch

Potential upcoming FDA decisions or pipeline news could offset the negative signal from the insider sell.

Relevance 8/10Novelty 8/10Timing: after filing today

Background

SEC Form 4 filing discloses insider transactions; this is the first public report of the sale.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ILMNBearishMedium confidence

Context

Director Keith A. Meister sold 669,596 shares of Illumina for $107M, reducing his holdings to 2.83M shares.

Expected impact

likely pressure as the market prices in the $107M insider sell

Evidence & confidence

The sale size is material for a mid‑cap biotech and the insider is a director; such transactions often lead to short‑term sell‑offs.

Market effects

Sector

May raise concerns for other biotech stocks as investors watch insider activity for sentiment cues.

Regional

Limited to U.S. markets where Illumina trades; no broader regional effect.

Global

Minimal global impact beyond Illumina's shareholder base.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event unrelated to company fundamentals; price may remain stable.

Key entities

company
Illumina, Inc.
US‑listed biotech company (ticker ILMN) whose director sold shares.
person
Meister Keith A.
Director of Illumina who executed the sale.

Read at source ← All news

OCT 26

$MRNAMed

Moderna’s Rally May Have Run Out of Steam. Here’s What to Watch Next

Moderna (MRNA) shares fell 20% after leaked trial data for its melanoma vaccine, despite analysts calling results 'strong.' The drop may signal the end of its 700% year-to-date rally. Merck (MRK), partnering on the vaccine, saw minimal impact. Analysts expect Merck to report strong earnings. BioNTech (BNTX) and Illumina (ILMN) are also mentioned.

aol.com3 min

OCT 13

$ILMNMed

Illumina Launches $1.0 Billion Unsecured Commercial Paper Program; Signs Dealer Agreements

Illumina established a $1.0 billion unsecured commercial paper program for general corporate purposes. The program allows short-term notes with maturities up to 397 days. A national bank will serve as the issuing and paying agent, with three dealers initially participating. No notes were outstanding as of the filing date.

tradingview.com1 min

OCT 5

$ILMNMed

Illumina (ILMN) Shares Skyrocket, What You Need To Know

Illumina (ILMN) shares rose 7.7% after analysts raised price targets, citing expected clinical sales growth and AI applications. The stock closed at $293.84, up 7.6%. Illumina's shares have seen significant volatility, with a 22.4% gain last year on strong earnings. The company has raised its full-year EPS guidance to $4.70. ILMN is up 119% YTD, reaching a 52-week high.

financialcontent.com2 min

SEP 24

$ILMNHighAI 8/10

Illumina Soars to New High After Index Win

Illumina (ILMN) shares hit a 52-week high after being added to the S&P 500 Equal Weighted Index. The company announced a $300M note offering, strong earnings, and raised full-year guidance. Analysts increased price targets, citing sustainable earnings and clinical sequencing demand. The stock's rise is driven by index inclusion, debt refinancing, and upgraded guidance, with future growth expected from its sequencer business model.

tipranks.com2 min

SEP 23

$GRALMed

This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval

Grail's Galleri test, which screens for 50 cancers, is under FDA review for approval. A major study failed to prove it detects later-stage cancers, causing skepticism among doctors. Grail's stock dropped 50% on the news but has since rebounded. FDA approval could lead to insurance coverage and impact competitors like Caris Life Sciences and Guardant Health.

morningstar.com6 min

SEP 18